Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin.
The antimetabolite 5-fluorouracil is frequently used in the therapy of various malignancies. Cardiotoxicity has frequently been described during treatment, but there is no common agreement on the need to perform cardiovascular monitoring of patients during 5-fluorouracil administration. We report the case of a young patient with an head-neck cancer on whom a continuous electrocardiogram recording was performed, documenting serious ventricular dysrhythmias in the presence of myocardial ischemia during 5-fluorouracil and cis-platin infusion.
Hrovatin
Enzo
E
UO Cardiologia-ARC, Dip. Emergenza, AO SM degli Angeli, Italy. e.hrovatin@tin.it
Viel
Elda
E
Lestuzzi
Chiara
C
Tartuferi
Lucia
L
Zardo
Fabio
F
Brieda
Marco
M
Dametto
Ermanno
E
Piazza
Rita
R
Antonini-Canterin
Francesco
F
Vaccher
Elda
E
Meneguzzo
Nereo
N
Nicolosi
Gian Luigi
GL
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004562:Electrocardiography; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D017202:Myocardial Ischemia / Q000139:chemically induced*
D000964:Antimetabolites, Antineoplastic; D002945:Cisplatin; D005472:Fluorouracil